CNS Pharmaceuticals (CNSP)
(Delayed Data from NSDQ)
$0.14 USD
0.00 (2.14%)
Updated Sep 24, 2024 03:58 PM ET
After-Market: $0.14 0.00 (-2.10%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for CNS Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 19 | 15 | 14 | 9 | 4 |
Income After Depreciation & Amortization | -19 | -15 | -14 | -9 | -4 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | -15 | -14 | -9 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -15 | -14 | -9 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -19 | -15 | -14 | -9 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -15 | -14 | -9 | -4 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -19 | -15 | -14 | -9 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.08 | 0.03 | 0.18 | 0.11 | 0.09 |
Diluted EPS Before Non-Recurring Items | -250.00 | -561.00 | -79.51 | -85.51 | -42.00 |
Diluted Net EPS (GAAP) | -250.00 | -561.00 | -79.51 | -85.51 | -42.00 |
Fiscal Year end for CNS Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.53 | 3.54 | 5.38 | 4.53 | 4.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.53 | -3.54 | -5.38 | -4.53 | -4.03 |
Non-Operating Income | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Interest Expense | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.53 | -3.54 | -5.38 | -4.52 | -4.02 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.53 | -3.54 | -5.38 | -4.52 | -4.02 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.53 | -3.54 | -5.38 | -4.52 | -4.02 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 0.38 | 0.17 | 0.11 | 0.08 | 0.08 |
Diluted EPS Before Non-Recurring Items | -6.72 | -20.50 | -47.50 | -54.00 | -52.00 |
Diluted Net EPS (GAAP) | -6.72 | -20.50 | -14.50 | -54.00 | -52.00 |